J Samuel Pérez-Blanco, Pharm.D, PhD Avda. Licenciado Méndez Nieto sn Full Assistant Professor 37003 Salamanca, Spain Tel: +34 677584202 Last update: June 26th, 2019 [email protected]

PROFESSIONAL EXPERIENCE Oct 2018 Assistant Professor of pharmacokinetics at Pharmacy and Pharmaceutical Currently Technology, Science Department, University of Salamanca, Spain  Application and development of new methodologies of Pharmacokinetic/Pharmacodinamic in approve drugs  Pharmacy and Master Degree lecturer  Supervision of undergraduate, graduate and PhD students (pharmacokinetics) Jul 2016 Research Scientist in Department at Janssen Pharmaceutica Sep 2018 (Johnson & Jonhson), Beerse, Belgium  Pharmacokinetic/Pharmacodinamic M&S activities  in clinical phases using mechanistic-based M&S  New Drug Approval portfolios (NDA) to regulatory agencies (FDA, EMA, etc.) Oct 2010 Assistant Professor of pharmacokinetics at Pharmacy and Pharmaceutical Jul 2016 Technology, Science Department, University of Salamanca, Spain  Research project supervision of pharmacy students in final year  Demonstration, seminars and classes of biopharmaceutics & pharmacokinetics  Development of education and training material and course organization  Virtual training in pharmaceutical care and laboratory inspection (Second Life)  Research fields: population pharmacokinetics (model building, evaluation, simulations), therapeutic drug monitoring, analytical methods Nov 2013 Head researcher of pharmacometrics sub-study of GEL-R-COMP 13 clinical Jul 2016 trial (ClinicalTrials.gov Identifier: NCT02012088)  Data management and collection (Case Report Form-RedCap)  Samples plasma management: samples reception, preservation and quantification (UHPLC-fluorescence detection)  Writing of pharmacokinetic sub-study (sampling, popPK & PK/PD analysis)  Interdisciplinary meetings, pharmacokinetic formation and consulting Oct 2010 PhD student at Pharmacy and Pharmaceutical Technology Science Department Mar 2016 University of Salamanca, Spain. Title “Clinical pharmacokinetic of doxorubicin in patients diagnosed with non-Hodgkin lymphoma”  UHPLC method development and validation (doxorubicin and doxorubicinol)  Data management and collection  Population pharmacokinetic modelling of doxorubicin and doxorubicinol (metabolite model), simulation and evaluation  Presentation of the results in international meetings (PAGE, PKUK, Argentina)  Research collaboration in Centre for Applied of Pharmacokinetic Research (CAPKR) University of Manchester, United Kingdom. Oct 14 – Jan 15 Supervisor: Leon Aarons . Monte Carlo simulations and population pharmacokinetic modelling  Research collaboration in Torrevieja Hospital, Alicante, Spain. Feb-Apr 2013 Supervisor: Belen Valenzuela . TDM of anticancer drugs, analytical methods, dosing adjustments, population pharmacokinetic with metabolites discussion with hospital clinicians EDUCATION School of Pharmacy, University of Salamanca, Salamanca, Spain 2010-2016 PhD in Pharmacy. Title “Clinical pharmacokinetic of doxorubicin in patients diagnosed with non-Hodgkin lymphoma” 2009-2010 Master´s degree “Design, development and drugs evaluation”. Score: 9.5/10 Specific formations on Pharmacometrics May 2019 Hands-on Experience with Model-informed Drug Development: Incorporating Population Variability into Mechanistic Prediction of PK and Modelling PK/PD [Certara], Kralow (Poland) Apr 2018 The Sheiner and Rowland Advance Course in Pharmacokinetics and , Sils-Maria, Switzerland Nov 2017 Intermediate pharmacokinetic workshop (Malcolm Rowland), Paris (France)

LANGUAGES Spanish Mother tongue English Professional, daily use

COMPUTER SKILLS / SOFTWARE PK NONMEM, Pirana, PKS (abbott) (advanced), WinNonlin (basic), PhysPK (basic) Scientific R (advanced), SPSS, RefWorks, Papers, Microsoft Office, Zotero

TEACHING EXPERIENCE Pharmacy specialist 2012-2016 Course “Drug quantification by HPLC” [campus.usal.es/galenica/hplc] 2011-2016 Course “TDM in Clinical Practice” [http://cursotdmsalamanca.es] Pharmacy degree & Masters Degree 2010-2016 Biopharmaceutics and pharmacokinetics, 3rd year of pharmacy degree 2011-2016 Pharmaceutical care, 4rd year of pharmacy degree 2018-2019 Pharmaceutical Technology, 4rd year of pharmacy degree 2015-2019 Clinic pharmacokinetic of anticancer drugs, students of master degree (cancer) 2018-2019 Preclinical pharmacokinetics studies, students of master degree (drug development)

MISCELLANEOUS Date of birth: 01/04/1985 Personal interest: basketball, volleyball, travelling and movies

AWARDS 2011 Corresponding Academic - Royal Academy of Medicine and Surgery of Valladolid 2012 Award for the Outstanding Master´s Graduate of the Year 2016 Best research article of 2016, Faculty of Pharmacy, University of Salamanca

RESEARCH PROJECTS 2019-2020 Characterization of the therapeutic index of vedolizumab treatment to personalize and optimize pharmacotherapy in patients with ulcerative colitis. Head researcher: Noemí Rebollo. Funding: Sociedad Española de Farmacia Hospitalaria (SEFH) 2019-2020 Determination of cardiovascular risk in community pharmacies. Head researcher: A. Martín Suárez. Funding: Lanzadera universitaria de proyectos con empresas plan TCUE 2018-2020. 2015-2016 Title Contribution to the dose optimization of imatinib to the integral patient treatment diagnosed with myeloid chronic leukaemia. Head researcher: A Sánchez. Funding: Gerencia Regional de Salud de Castilla y León (SACYL) 2014-2015 Title “Population pharmacokinetic of conventional and liposome doxorubicin in patients diagnosed with lymphoma: cardiotoxicity evaluation. Head researcher: MJ Garcia. Funding: University of Salamanca, Spain 2012-2014 Title “Physiological models as a tool in translational and individualised medicine in the therapeutic field”. Head researcher: A Sánchez Navarro. Funding: Junta de Castilla y León, Spain

PUBLICATIONS  Eva María Sáez Fernández*, Jonás Samuel Pérez-Blanco*, José M Lanao, M Victoria Calvo & Ana Martín-Suárez (2019) Evaluation of renal function equations to predict amikacin clearance, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2019.1637253; *Contributed equally as first author.  Martin-Suarez A, Sanchez-Hernandez JG, Medina-Barajas F, Pérez-Blanco JS, Lanao JM, Garcia-Cuenllas Alvarez L, Calvo MV. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia. Expert Rev Clin Pharmacol. 2017 Aug;10(8):911-917. doi: 10.1080/17512433.2017.1344096  Pérez-Blanco, J.S., Santos-Buelga, D., Fernández de Gatta, M., Hernández-Rivas, J., Martín, A. and García, M. (2016). Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. British Journal of Clinical Pharmacology. DOI: 10.1111/bcp.13070  Pérez-Blanco JS, del Mar Fernández de Gatta M, Hernández-Rivas JM, Sánchez MJG, Marinero MLS, López FG. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 1;955- 956:93–7  García-Peñalvo FJ, Cruz-Benito J, Maderuelo C, Pérez-Blanco JS, Martín-Suárez A. Usalpharma: A Cloud-Based Architecture to Support Quality Assurance Training Processes in Health Area Using Virtual Worlds. Sci World J. 2014, Article ID 659364, 10 pages, 2014. doi: 10.1155/2014/659364  Maderuelo, C; Martin-Suarez, A; Pérez-Blanco, JS; Zazo, H; Cruz-Benito, J; Domínguez-Gil, A. Facility-based inspection training in a virtual 3D-laboratory. Acred Qual Assur. 2014, Vol. 19,403-09. doi: 10.1007/s00769-014-1065-44

COMMUNICATIONS ORAL  Pérez-Blanco JS, Santos Buelga D, Hernández Rivas JM, Fernández de Gatta MM, García MJ. Modelo farmacocinético poblacional de doxorrubicina y doxorrubicinol en pacientes diagnosticados de linfoma no Hodgkin. 6th Jornadas de Modelización y Simulación en Biomedicina, Madrid, España, Nov 2015  Pérez-Blanco JS, Mangas V. Covariate model building: GAM & SCM. 3rd Workshop en Modelización Farmacocinética y Farmacodinámica, Barcelona, Spain, Nov 2014  Pérez-Blanco JS. Population pharmacokinetic of doxorubicin and doxorubicinol in haematological patients. 4rd Uppsala Pharmacometric Summer School, Uppsala, Sweden, Aug 2014 POSTER  Carlos Pérez-Ruixo*, Jonás Samuel Pérez-Blanco*, Caly Chien, Margaret Yu, Daniele Ouellet, Juan-José Pérez-Ruixo, Oliver Ackaert. Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects. Population Approach Group of Europe meeting 28 (2019), Stockholm, Sweeden. [abstract=8984]; *Contributed equally as first author.  Alberto Russu, Jonás Samuel Pérez-Blanco, Peter Van Der Ark, Vikash Sinha, Adam Savitz, Peter De Boer, Jay B. Saoud, Partha Nandy, Juan Jose Perez Ruixo. Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist. XXVI meeting of Population Approach Group of Europe (PAGE). Budapest, Hungría, 6-9 de Junio de 2017 (Internacional). ISSN 1871-6032. PAGE 26 (2017) Abstr 7366 [abstract=7366]  Sánchez JG, Medina FP, Martín-Suárez A, Pérez-Blanco JS, Lanao JM, Calvo MV. Pharmacokinetics of digoxin during pregnancy. 44th ESCP Symposium on clinical pharmacy. Lisbon, Portugal, Oct 2015  Pérez-Blanco JS, Santos Buelga D, Hernández Rivas JM, Fernández de Gatta MM, García MJ. Modelo farmacocinético poblacional de doxorrubicina y doxorrubicinol en pacientes diagnosticados de linfoma no Hodgkin. 3rd Congreso sudamericano de biofarmacia y farmacocinética (BFFC). Córdoba, Argentina, Nov 2015  Pérez-Blanco J.S., Teixeira P., Otero M.J., Laso Lucas E., García Sánchez M.J., Santos Buelga D. Age influence on clearance of phenobarbital in paediatric patients. 24rd Population Group Approach in Europe, Crete, Greece, Jun 2015 [abstract=3617]  JS Pérez-Blanco, MJ Garcia Sánchez, MM Fernández de Gatta, JM Hernández-Rivas, D Santos Buelga. Development of a popPK model of doxorubicin and doxorubicinol in haematological patients. PKUK, Bath, United Kingdom, Nov 2014  García Sánchez MJ, Pérez-Blanco JS, de Jesús Valle MJ, Sánchez Navarro A. PBPK analysis of doxorrubicin tissue uptake by Simcyp® simulator: influence of gender related variables. 23rd Population Group Approach in Europe, Alicante, Spain, Jun 2014 [abstract=3297]

REFERENCES JJ Pérez-R Juan José Pérez Ruixó, Pharm.D, PhD Senior Scientific Manager of Pharmacometrics Janssen Research and Development, Global Clinical Pharmacology Beerse, Belgium Email: mailto:[email protected] MJ Garcia Mª José Garcia Sánchez, Pharm.D, PhD Professor of pharmacometrics at University of Salamanca Pharmacy and Pharmaceutical Technology – Pharmaceutical Sciences Department, School of Pharmacy, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain Phone: +34 669 810 988 Email: [email protected] L Aarons Leon Aarons, BSc, MSc, PhD Professor of Pharmacometrics at University of Manchester Manchester Pharmacy School – Stopford Building, Room 3.35 Oxford Road, Manchester, M13 9PT, United Kingdom Phone: +44 (0) 161 275 2357 Email: [email protected]